ClinicalTrials.gg
RecruitingNCT07686718Updated Jul 7, 2026

To Establish Whether Individuals With Premenstrual Dysphoric Disorder (PMDD) Demonstrate a Different Luteal-phase Sex Hormone Profile and Ratio Compared With Asymptomatic Controls.

An observational study in Premenstrual Dysphoric Disorder ( PMDD), sponsored by Lancaster University. Recruiting at 1 site in United Kingdom. Open to female participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-07-07.

Sponsored by Lancaster University · Observational

How we know

From the registry’s dates

  • Started May 2026; still recruiting 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-control
Time perspective
Prospective
Enrollment
50
Ages
18 Years to 45 Years
Sex
Female
01

Study summary

The aim of this project is to compare the ovarian hormone levels 7 days after ovulation and progesterone:oestradiol ratios between PMDD individuals and a control cohort (case control study).

Read the detailed description

Premenstrual dysphoric disorder (PMDD) is a severe cyclical disorder characterised by affective, cognitive and physical symptoms occurring during the luteal phase of the menstrual cycle and resolving shortly after the onset of menstruation. Although circulating ovarian hormone concentrations are generally considered to be within physiological reference ranges, increasing evidence suggests that altered sensitivity to normal hormonal fluctuations, rather than absolute hormone concentrations alone, may contribute to symptom development.

The progesterone-to-oestradiol ratio has been proposed as a potential biological marker of luteal hormonal balance; however, this has not been systematically evaluated in individuals with PMDD compared with asymptomatic controls.

This observational case-control study will compare serum progesterone concentrations, serum oestradiol concentrations, and the progesterone-to-oestradiol ratio during the mid-luteal phase between participants with PMDD and healthy controls. Hormone measurements will be obtained following confirmation of ovulation using a urinary luteinising hormone (LH) surge, with blood sampling performed approximately seven days after the LH surge to standardise assessment within the mid-luteal phase.

The findings will provide preliminary evidence regarding whether alterations in the progesterone-to-oestradiol ratio are associated with PMDD and may inform future mechanistic studies investigating the endocrine basis of the disorder.

02

Conditions studied

  • Premenstrual Dysphoric Disorder ( PMDD)

Keywords

  • PMDD
  • premenstrual dysphoric disorder
  • oestrogen
  • progesterone
  • ratios
03

In context

Premenstrual Dysphoric Disorder

42 studies on the registry are indexed under Premenstrual Dysphoric Disorder; 10 are open to participants now.

Browse Premenstrual Dysphoric Disorder studies →

Lead sponsor

Lancaster University is the lead sponsor of 21 studies on the registry; 4 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

adults of reproductive age who experience menstrual cycles and have a diagnosis of, or symptoms consistent with, Premenstrual Dysphoric Disorder (PMDD) or a control population

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Aged 18-45 years old (adults but less than the typical perimenopausal age so there is not added bias/variable)
  • Regular menstrual cycles (21-35 days for the last 3 months)
  • Willing and able to complete a questionnaire (no new clinical diagnosis given)
  • Use home urine LH test strips to detect ovulation
  • Attend a single in person on site in Lancaster mid luteal blood test sample appointment (approx 7 days post LH surge)
  • Provide written
  • Have sufficient English language skills to understand the patient information
  • Be either in Group 1 or group 2 Group 1 (PMDD group ie case group) - self reported prior diagnosis of PMDD made by a healthcare professional (GP, psychiatrist, gynaecologist) Group 2 (Control group ie comparison group) - no prior diagnosis of PMDD made by a healthcare professional and no history of premenstrual mood symptoms on screening

Exclusion criteria

Exclusion criteria

  • Current use or use in the last 3 months of hormonal such as the combined oral contraceptive pill, the progestogen only pill, the implant, the injection, hormonal coil (Mirena, Kyleena) or patch/ring.
  • Current use or use in the last 3 months of any hormone replacement therapy (e.g. combined oestrogen and progesterone, oestrogen and Mirena coil combination, oestrogen alone if had a hysterectomy, or progesterone alone) or GnRH analogues use
  • On a selective serotonin reuptake inhibitor (SSRI) with a recent initiation or dose change within the last 3 months
  • Pregnant, breastfeeding or within 3 months post partum
  • Irregular menstrual cycles (outside the 21-35 day window)
  • Surgical menopause
  • Premature ovarian insufficiency
  • Other endocrine disorders e.g. uncontrolled thyroid disease, high prolactin, cushing's syndrome, polycystic ovarian syndrome)
  • Regular systemic use or use of other medications known to affect sex hormone within the last 3 months
  • Severe mental health issues that impair consent or participation
  • Needle phobic so that venepuncture is intolerable
  • The use of the emergency contraceptive pill either 3 months prior to the study or during the study.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Observational model
Case-control
Time perspective
Prospective
Enrollment
50 participants (estimated)
Target follow-up
6 Months
Patient registry
Yes
Biospecimen retention
Samples without dna

Groups and cohorts

  • control group

    oestrogen and progesterone levels and ratios 5-7 days post ovulation

  • PMDD group

    oestrogen and progesterone levels and ratios 5-7 days post ovulation

06

What researchers measure

Primary outcomes

  1. blood level

    progesterone

    Time frame: 5-7 days post ovulation

  2. blood level

    oestrogen

    Time frame: 5-7 days post ovulation

  3. blood test

    progesterone to oestrogen level

    Time frame: 5-7 days post ovulation

07

Study locations

1 of 1 sites recruiting
  • Lancaster University
    Lancaster, Lancashire LA1 4YW, United Kingdom
    Recruiting
    • Milli Raizazda, MBCHB Hons · Contactm.raizada2@lancaster.ac.uk · +44 (0)1524 65201
    • Chris Gaffney, BSc (Hons.) MSc PhD SFHEA · Contactc.gaffney@lancaster.ac.uk · +44 (0)1524 65201
    • milli raizada, MBCHB Hons · Principal investigator
    • chris gaffney, BSc (Hons.) MSc PhD SFHEA · Sub investigator
08

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Undecided — Individual participant data will not be shared publicly because the study involves sensitive health information and there is a risk that participants could be identifiable despite de-identification procedures. Data will be stored and managed in accordance with ethical approval, data protection regulations, and participant consent. Aggregate, anonymised results will be disseminated through publications, presentations, and other scholarly outputs

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started May 2026 (actual). Primary completion is estimated for Aug 2027, 14 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 22, 2026
First posted
Jul 7, 2026
StartActual
May 5, 2026
Primary completionEst.
Aug 1, 2027
CompletionEst.
Aug 1, 2027
Last update
Jul 7, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 7, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07686718
Lead sponsor
Lancaster University
Responsible party
Milli Raizada (Senior Clinical Lecturer, Lancaster University) — Principal investigator
First posted
Jul 7, 2026
Start date
May 5, 2026
Primary completion
Aug 1, 2027 (estimated)
Completion
Aug 1, 2027 (estimated)
Last update
Jul 7, 2026

Study contacts

Milli Raizada, MBCHB Hons
Contact
m.raizada2@lancaster.ac.uk
+44 (0)1524 65201
Chris Gaffney, BSc (Hons.) MSc PhD SFHEA
study director · Lancaster University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion